ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

Recommended AI News: Kinara Forms Collaborations with Ampere and Mirasys to Drive Widespread Adoption of AI Solutions

“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.

ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.

Recommended AI News: DataCore Software Unveils Next-Gen Capabilities in SANsymphony and Swarm Storage Offerings

“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

[To share your insights with us, please write to sghosh@martechseries.com]